Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient treatment needs and the clinical and financial needs of the treatment provider.
| Revenue (Most Recent Fiscal Year) | $18.79M |
| Net Income (Most Recent Fiscal Year) | $1.19M |
| PE Ratio (Current Year Earnings Estimate) | 28.10 |
| PE Ratio (Trailing 12 Months) | 38.32 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.21 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.82 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 33.60 |
| Pre-Tax Margin (Trailing 12 Months) | 8.45% |
| Net Margin (Trailing 12 Months) | 8.38% |
| Return on Equity (Trailing 12 Months) | 10.60% |
| Return on Assets (Trailing 12 Months) | 8.05% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.07 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.71 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 2.27 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.10 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.06 |
| Earnings per Share (Most Recent Fiscal Year) | $0.11 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.16 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Common Shares Outstanding | 10.86M |
| Free Float | 10.13M |
| Market Capitalization | $45.78M |
| Average Volume (Last 20 Days) | 0.04M |
| Beta (Past 60 Months) | 1.55 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 41.10% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |